2-acetyl-6-fluoro-5-methylbenzothiazole | 214854-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-acetyl-6-fluoro-5-methylbenzothiazole
• 英文别名: Ethanone, 1-(6-fluoro-5-methyl-2-benzothiazolyl)-(9CI)；1-(6-fluoro-5-methyl-1,3-benzothiazol-2-yl)ethanone
• CAS: 214854-88-3
• 化学式: C₁₀H₈FNOS
• 分子量: 209.244
• InChiKey: FSJCCDCYNZYGAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-fluoro-5-methylbenzothiazole 以93%的产率得到2-acetyl-6-fluoro-5-methylbenzothiazole
  参考文献：
  名称：

  Pyrazole derivatives and COX inhibitors containing them

  摘要：

  本发明旨在提供具有强效药理作用并对COX-2具有选择性抑制活性的抗炎药物，从而预期减少胃黏膜紊乱等不良反应。本发明涵盖了以下式（1）的化合物：其中R.sup.1为氢或卤素，R.sup.2和R.sup.3分别独立为氢、卤素、较低烷基、较低烷氧基、羟基或较低烷酰氧基，R.sup.4为较低卤代烷基或较低烷基，X为硫、氧或NH，Y为较低烷基硫基、较低烷基磺酰基或磺酰胺基，具有优越的抗炎活性，并高度抑制炎症部位中诱导的COX-2，在胃、肾等器官中对存在的COX-1的抑制作用较小。包括本发明化合物的药物剂被提供为选择性COX-2抑制剂，并且抗炎药物很少伴随对胃黏膜的攻击等不良作用。

  公开号：

  US06136831A1

文献信息

• PYRAZOLE DERIVATIVES AND COX INHIBITORS CONTAINING THEM
  申请人：Grelan Pharmaceutical Co., Ltd.

  公开号：EP1006114A1

  公开（公告）日：2000-06-07

  Antiinflammatory agents which are excellent in pharmacological effects and exhibit selective COX-2 inhibiting activity leading to an expectation of reduction in the adverse effects such as gastric mucosal disturbances. Compounds of general formula (I) have excellent antiinflammatory activity, and exhibit potent inhibitory action against COX-2 induced at an inflamed site with little inhibitory action against COX-1 always present in the stomach, kidney and so on, (wherein R1 is hydrogen or halogeno; R2 and R3 are each hydrogen, halogeno, lower alkyl, lower alkoxy, hydroxyl or lower alkanoyloxy; R4 is halogenated lower alkyl or lower alkyl; X is sulfur, oxygen or NH; and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl). Accordingly, drugs containing the compounds are useful as antiinflammatory agents reduced in the adverse effects such as gastric mucosal disturbances by virtue of the selective inhibitory activity of the compounds against COX-2.

  抗炎剂具有卓越的药理作用，并具有选择性 COX-2 抑制活性，有望减少胃黏膜紊乱等不良反应。通式（I）化合物具有优异的抗炎活性，对发炎部位诱导的 COX-2 具有强效抑制作用，而对始终存在于胃、肾等部位的 COX-1 几乎没有抑制作用；R2和R3分别是氢、卤素、低级烷基、低级烷氧基、羟基或低级烷酰氧基；R4是卤代低级烷基或低级烷基；X是硫、氧或NH；Y是低级烷硫基、低级烷磺酰基或氨基磺酰基）。因此，含有这些化合物的药物可作为消炎药使用，由于这些化合物对 COX-2 的选择性抑制活性，可减少胃黏膜紊乱等不良反应。
• US6136831A
  申请人：——

  公开号：US6136831A

  公开（公告）日：2000-10-24
• Pyrazole derivatives and COX inhibitors containing them
  申请人：Grelan Pharmaceutical Co., Ltd.

  公开号：US06136831A1

  公开（公告）日：2000-10-24

  The purpose is to provide anti-inflammatory agents which have potent pharmacological actions and exert a selective inhibitory activity on COX-2, thereby being expected to reduce adverse effects such as disorders in gastric mucosa. The present invention encompasses a compound of the formula (1): wherein R.sup.1 is hydrogen or halogen, R.sup.2 and R.sup.3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy, R.sup.4 is lower haloalkyl or lower alkyl, X is sulfur, oxygen or NH, and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl, which exerts superior anti-inflammatory activity, and highly inhibits COX-2 induced in inflamed sites, with less inhibitory action on COX-1 present in stomach, kidney, etc. Pharmaceutical agents comprising the compound of the present invention are provided as selective COX-2 inhibitors, and anti-inflammatory agents rarely accompanying adverse actions including attacks on gastric mucosa.

  本发明旨在提供具有强效药理作用并对COX-2具有选择性抑制活性的抗炎药物，从而预期减少胃黏膜紊乱等不良反应。本发明涵盖了以下式（1）的化合物：其中R.sup.1为氢或卤素，R.sup.2和R.sup.3分别独立为氢、卤素、较低烷基、较低烷氧基、羟基或较低烷酰氧基，R.sup.4为较低卤代烷基或较低烷基，X为硫、氧或NH，Y为较低烷基硫基、较低烷基磺酰基或磺酰胺基，具有优越的抗炎活性，并高度抑制炎症部位中诱导的COX-2，在胃、肾等器官中对存在的COX-1的抑制作用较小。包括本发明化合物的药物剂被提供为选择性COX-2抑制剂，并且抗炎药物很少伴随对胃黏膜的攻击等不良作用。